抗癌性吲哚喹唑啉衍生物的定量构效关系

用量子化学密度泛函理论(DFT)、分子力学(MM＋)及回归分析方法,对一系列抗癌性吲哚喹唑啉衍生物进行了定量构效关系(QSAR)的研究.通过回归分析,筛选了影响抗癌活性的主要因素,建立了定量构效关系方程.结果表明,化合物的最低未占据分子轨道(LUMO)与最高占据分子轨道(HOMO)之间的能量差(ΔεL-H)、分子的疏水性(lgP)以及环D上的总电荷(ΣQD)和环D上R1取代基的第一个原子的净电荷(QFR1)是影响化合物抗癌活性的主要因素.所得模型对化合物抗癌活性有较好的预测效果. 同时, 与ΔεL-H密切相关的LUMO轨道能量及共轭平面面积对药物的DNA-结合及其活性起着十分重要的作用,可通过选取具有较强的拉电子性质同时又能与本系列化合物的骨架形成更大共轭体系的取代基R1,设计抗癌活性较高的化合物.     

DFT法研究阴离子识别剂[Ru（bpy）2L]2+（L=H2biim,H2bbim）去质子后结构变化

配合物[Ru(bpy)2(H2biim)](PF6)2(1)(bpy=2,2′-联吡啶,H2biim=2,2′-联咪唑)和[Ru(bpy)2(H2bbim)](PF6)2(4)(H2bbim=2,2′-苯并联咪唑)是良好的阴离子识别剂.用密度泛函理论方法研究了2种阴离子识别剂脱去质子后的几何结构和电子结构的变化.计算结果表明:脱去质子后配合物HOMO轨道上电子云分布由中心钌原子转移到(苯并)联咪唑上,而LUMO轨道虽然能量增加但电子云仍然分布在bpy配体上;另外,最高占居轨道HOMO与最低空轨道LUMO的能量差ΔεL-H逐渐减小,相对于配合物的吸收波长增大,所以分子的吸收峰发生红移,这与实验现象相吻合。     

1,10-邻菲咯啉衍生物La(III)配合物的电子结构与抗癌活性

对一系列1,10-邻菲咯啉衍生物La(III)配合物,用密度泛函(DFT)法,在B3LYP/LanL2DZ水平进行理论研究.探讨了配合物的电子结构与其抗癌活性的关系,发现偶极矩(μ)和原子净电荷(Q)都对配合物的抗癌活性有影响,但不起决定性作用,而配合物的LUMO的能量(ELUMO)是决定其抗癌活性强弱的主要因素.并且揭示了配体上侧链烷基链的增长并不是获得高活性分子的最佳途径,而侧链上苯环引入却为设计活性更强的分子提供了可能性.基于理论研究结果,设计了三个具有更高抗癌活性的新配合物.     

利用吡啶衍生物主配体共轭效应调控铱配合物发光颜色(英文)

利用2-苯基吡啶及其衍生物为主配体、四苯基膦酰亚胺为辅助配体合成了3个铱配合物Ir(ppy)2tpip(Hppy:2-苯基吡啶,Htpip:四苯基膦酰亚胺)、Ir(npy)2tpip(Hnpy:2-(1-萘基)吡啶)和Ir(pnpy)2tpip(Hpnpy:2-(9-菲基)吡啶)。它们的结构通过1H NMR和MALDI-TOF质谱进行了表征,其中配合物Ir(ppy)2tpip还进一步通过晶体结构分析验证。主配体从苯环到萘环和菲环的改变增加了配合物的π共轭,减小了能级差,导致了3种配合物的磷光发射光谱从516 nm红移到600和633 nm(从绿光到红光),发光量子效率也从0.36增加到0.51和0.53。从量化计算的结果可以看出,这种共轭效应增加了主配体的电子密度,提高了配合物的LUMO能级。配合物结构和发射性质之间的关系规律为设计不同发光颜色的铱配合物提供了思路。     

含硫希夫碱过渡金属配合物及其抗癌活性的研究Ⅴ.3-乙酰吡啶缩氨基硫脲与ZnX_2.CuX_2.NiX_2的配合物及其抗癌活性

合成和表征了3-乙酰吡啶缩氨基硫脲与Zn(Ⅱ)Cu(Ⅱ)Ni(Ⅱ)的六个配合物,并用体外试管法测试了配体和配合物的抗癌活性。结果表明:3-乙酰吡啶是通过亚胺基N原子和S原子与金属离子形成配合物,这些配合物的抗癌活性均强于自由配体,Zn(Ⅱ)和Cu(Ⅱ)配合物对腹水癌细胞的杀死率均为100%.     

含二胺均三嗪衍生物的钌(II)配合物的合成、晶体结构、电化学及光谱性质

钌(II)多吡啶配合物在光化学、物理学、光催化、电化学、光电化学、电子转移和能量传递、分子组装等领域一直扮演者非常重要的角色. 钌(II)多吡啶配合物的分子结构具有很大的可塑性, 通过往配体上接入各种不同类型官能团, 可以设计出各种各样具有不同分子识别功能的分子器件. 本文在钌(II)配合物中引入二氨均三嗪基团, 设计合成了三个新型的钌(II)多吡啶配合物 [Ru(bpy)₂(1-IQTNH)](ClO₄)2 (1), [Ru(bpy)₂(2-QTNH)](ClO₄)₂ (2) 和 [Ru(bpy)₂(3-IQTNH)](ClO₄)₂ (3) (bpy = 2,2′-bipyridine, 1-IQTNH = 6-(isoquinolin-1-yl)-1,3,5-triazine-2,4- diamine, 2-QTNH = 6-(quinolin-2-yl)-1,3,5-triazine-2,4-diamine, 3-IQTNH = 6-(isoquinolin-3-yl)-1,3,5-triazine-2,4- diamine). 通过元素分析、ES-MS、1H NMR进行结构表征, 确证了它们的组成. 用X射线单晶衍射测定了配合物[Ru(bpy)₂(2-QTNH)](ClO₄)₂·2H₂O和[Ru(bpy)₂(3-IQTNH)](ClO₄)₂的晶体结构. 配合物2和3都属单斜晶系. 晶体结构表明, 配合物中钌(II)均具有畸变八面体几何构型. 分子计算表明配体1-IQTNH和2-QTNH在电子结构性质方面很相似并具有比bpy和3-IQTNH能量更低的LUMO. 实验结果与分子计算一致, 电化学实验证明在配合物1和2中, 最稳定的LUMO轨道位于配体1-IQTNH和2-QTNH, 而配合物3中最稳定的LUMO轨道位于配体bpy. 从吸收光谱中可观察到, 由于具有比bpy更大的?电子共轭体系, 配合物1和2的MLCT峰都发生了明显红移. 以上实验结果表明, 配体结构的改变, 导致配合物1~3表现出和[Ru(bpy)₃]²⁺不同程度的性质差异.     

含不同芳香取代基的肼基二硫代甲酸甲酯-Ga~(3+)配合物的合成及抑菌活性

设计合成了4种含不同芳香取代基团的肼基二硫代甲酸甲酯配体(2-乙酰基吡啶肼基二硫代甲酸甲酯(L1-H)、2-甲酰基吡啶肼基二硫代甲酸甲酯(L2-H)、2-甲酰基噻吩肼基二硫代甲酸甲酯(L3-H)、2-甲酰基水杨醛肼基二硫代甲酸甲酯(L4-H))的镓配合物,对它们的抑菌活性进行了测试,并讨论了配体分子中不同芳香取代基对配合物抑菌活性的影响。在模拟生理条件下,L-H与Ga3+生成较稳定的单核配合物[Ga(L1)2]NO3(1)、[Ga(L2)2]NO3(2)、[Ga(L3)2]NO3(3)、[Ga(L4)2]NO3(4),各配合物对金黄色葡萄球菌和大肠杆菌表现出比Ga(NO3)3·9H2O强的抑制活性,抑制金黄色葡萄球菌的能力高于大肠杆菌,其中,1和2的活性比相应配体高,其余2个配合物与其配体之间无明显活性差异。L1-H和L2-H分子中吡啶基的较强吸电子效应可能是1和2具有较强抑菌活性的主要原因。4种配合物抑制黑曲霉生长的活性同样高于Ga(NO3)3·9H2O,其中3最强,并显著高于L3-H,其余配合物与相应配体间无活性差异。     

1,10-邻菲咯啉衍生物La(Ⅲ)配合物的电子结构与抗癌活性

对一系列1,10-邻菲咯啉衍生物La（Ⅲ）配合物,用密度泛函（DFT）法,在B3LYP／LanL2DZ水平进行理论研究。探讨了配合物的电子结构与其抗癌活性的关系,发现偶极矩（μ）和原子净电荷（Q）都对配合物的抗癌活性有影响,但不起决定性作用,而配合物的LUMO的能量（ELUMO）是决定其抗癌活性强弱的主要因素。并且揭示了配体上侧链烷基链的增长并不是获得高活性分子的最佳途径,而侧链上苯环引入却为设计活性更强的分子提供了可能性。基于理论研究结果,设计了三个具有更高抗癌活性的新配合物。     

四个Cd(Ⅱ)配位聚合物:辅助配体对晶体结构以及荧光性能的影响

采用溶剂热的方法,将配位模式丰富的多羧酸有机配体5-(2-硝基-4-羧基苯氧基)-间苯二甲酸(H3ncpoi)与Cd~(2+)离子以及不同的辅助配体原位组装而成4个新的配位聚合物晶体:[Cd(Hncpoi)(2,2′-bpy)(H2O)]n(1),{[Cd2(Hncpoi)2(bpyp)(H2O)4]·3H2O}n(2),{[Cd2(Hncpoi)2(azpy)(H2O)2]·2H2O}n(3),{[Cd2(Hncpoi)2(dpe)(H2O)2]·2H2O}n(4),其中H3ncpoi为5-(2-硝基-4-羧基苯氧基)-间苯二甲酸,2,2′-bpy为2,2′-联吡啶,bpyp为1,4-二-吡啶基-4-亚甲基-哌嗪,azpy为4,4′-偶氮吡啶,dpe为1,2-二-(4-吡啶基)乙烯。对4个配合物进行了X射线单晶衍射、粉末衍射,元素分析、热重、荧光光谱等表征。X射线单晶结构分析表明,配合物1,2具有一维链状结构,而配合物3,4则具有二维(4,4)格子层状结构,一维链和二维层之间通过分子间作用力连接成三维超分子结构。进一步研究表明,辅助配体的构型、配位方式等对晶体结构具有决定性作用。与此同时,对几个配合物的荧光光谱进行分析,发现不同的辅助配体对配合物的荧光性能有着显著的影响。     

Cu(Ⅱ),Ni(Ⅱ),Co(Ⅱ),Mn(Ⅱ),Zn(Ⅱ)和Cd(Ⅱ)的乙基3-(2-氨硫化亚肼基)-2-(羟胺基)丁烯酸酯配合物:合成、表征和细胞毒性(英文)

合成了Cu(Ⅱ),Ni(Ⅱ),Co(Ⅱ),Mn(Ⅱ),Zn(Ⅱ)和Cd(Ⅱ)的乙基3-(2-氨硫化亚肼基)-2-(羟胺基)丁烯酸酯配合物(H2L)并用元素分析,DTA热分析,IR,UV-Vis,1H-NMR,质谱,顺磁共振以及磁矩,电导率测量等对合成的配合物进行表征。摩尔电导率测量结果证明合成的配合物为非电解质。光谱数据表明配体分别表现为一元的三齿配体,一元的二齿配体,中性的二齿配体,中性的三齿配体,一元的四齿配体或二元的四齿配体通过席夫碱的氮原子,氨基硫脲中的氮原子,肟中的氮原子和硫酮中的硫原子与金属离子键合生成围绕金属离子的四面体或平面正方形构型。固态Cu(Ⅱ)(2),(3),(4)和(5)的配合物顺磁共振谱表明其为轴向对称,但(10~15)的配合物却为各向异性。配体和配合物(2),(3),(10),(13),(16)和(19)由于它们对乳腺癌(MCF-7细胞系)和肝癌(HePG-2细胞系)的抑制作用而表现出潜在的抗癌活性。     

Dichlorobis(2-phenylazopyridine)ruthenium(II) complexes: characterisation, spectroscopic and structural properties of four isomers

The didentate ligand 2-phenylazopyridine (azpy) can--in theory--give rise to five different isomeric complexes of the type [Ru(azpy)2Cl2], of which three have been known since 1980. The molecular structures of the cis-dichlorobis(2-phenylazopyridine) ruthenium(II) complexes alpha-[Ru(azpy)2Cl2] and beta-[Ru(azpy)2Cl2](in which the coordinating pyridine nitrogen atoms are in mutually trans and cis positions, respectively, whilst the azo nitrogen atoms are in mutually cis positions) were unambiguously determined in the early 1980s. The third isomer, gamma-[Ru(azpy)2Cl2], has for two decades, erroneously, been assumed to be the all-trans isomer. In a recent communication we have proven that for this gamma isomer the chloride ions are indeed in a trans geometry, but the pyridine nitrogen and azo nitrogen atoms of the two azpy ligands are in mutually cis geometries. In this paper the isolation of a fourth isomer is presented, the hitherto unknown delta-[Ru(azpy)2Cl2]. The isomeric structure of delta-[Ru(azpy)2Cl2] has been determined by 1H-NMR spectroscopy and single-crystal X-ray diffraction analysis, and is the all-trans isomer. The bis(azpy)-ruthenium(II) isomers are of interest because of the pronounced cytotoxicity they exhibit against tumour cell lines and could be very useful in the search for structure-activity relationships of antitumour-active ruthenium complexes, as among the isomers there is a significant difference in activity. It is of paramount importance to have a good understanding of the structural and spectroscopic properties of these complexes, which in this paper are compared and discussed, with a particular emphasis on 1D and 2D 1H NMR spectroscopies.     

Binding to DNA purine base and structure-activity relationship of a series of structurally related Ru(II) antitumor complexes: a theoretical study

The thermodynamics of the binding of a series of structurally related Ru(II) antitumor complexes, that is, alpha-[Ru(azpy)2Cl2] 1, beta-[Ru(azpy)2Cl2] 2, alpha-[Ru(azpy)(bpy)Cl2] 3, and cis-[Ru(bpy)2Cl2] 4 to DNA purine bases (gunine, adenine at N7 site) has been studied by using the DFT method. The binding of imine form of 9-methyladenine (9-MeAde) to the Ru(II) moiety in a didentate fashion via its N6 and N7 atoms was also considered. The geometrical structures of the DNA model base adducts were obtained at the B3LYP/(LanL2DZ + 6-31G(d)) level in vacuo. The following exact single-point energy calculations were performed at the B3LYP/(LanL2DZ(f)+6-311+G(2d, 2p)) level both in vacuo and in aqueous solution using the COSMO model. The bond dissociation enthalpies and free energies, reaction enthalpies and free energies both in the gas phase and in aqueous solution for all considered Ru(II)-DNA model base adducts were obtained from the computations. The calculated bond dissociation enthalpies and free energies allow us to build a binding affinity order for the considered Ru(II)-DNA model base adducts. The theoretical results show that the guanine N7 is a preferred site for this series of complexes and support such an experimental fact that alpha-[Ru(azpy)(bpy)(9-EtGua)H2O](2+) (3-(9-EtGua)) is isomerized to alpha'-[Ru(azpy)(bpy)(9-EtGua)H2O](2+) (3'-(9-EtGua)). On the basis of structural and thermodynamical characteristics, the possible structure-activity relationship was obtained, and the distinct difference in cytotoxicities of this series of structurally related antitumor complexes was explained theoretically.     

Synthesis, characterization, and crystal structure of alpha-[Ru(azpy)2(NO3)2] (azpy = 2-(phenylazo)pyridine) and the products of its reactions with guanine derivatives

The synthesis and characterization of alpha-[Ru(azpy)2(NO3)2], 1, are reported (azpy is 2-(phenylazo)pyridine; alpha indicates the isomer in which the coordinating pairs ONO2, N(py), and N(azo) are cis, trans, and cis, respectively). The solid-state structure of 1 has been determined by X-ray crystallography. Crystal data: orthorhombic a = 15.423(5) A, b = 14.034(5) A, c = 10.970(5) A, V = 2374(2) A3, space group P2(1)2(1)2(1) (No. 19), Z = 4, Dcalc = 1.655 g cm-3. The structure refinement converged at R1 = 0.042 and wR2 = 0.118 for 3615 unique reflections and 337 parameters. The octahedral complex shows monodentate coordination of the two nitrate ligands. The Ru-N(azo) bond distances (2.014(4) and 1.960(4) A), slightly shorter than the Ru-N(py) bonds (2.031(4) and 2.059(4) A), agree well with the pi-back-bonding ability of the azo groups. The binding of the DNA-model bases 9-ethylguanine (9egua) and guanosine (guo) to 1 has been studied and compared with previously obtained results for the binding of model bases to the bis(bipyridyl)ruthenium(II) complex. The ligands 9egua and guo appear to form monofunctional adducts, which have been isolated as alpha-[Ru(azpy)2(9egua)Cl]PF6, 2, alpha-[Ru(azpy)2(9egua)(H2O)]-(PF6)2, 3, alpha-[Ru(azpy)2(guo)(H2O)](PF6)2, 4, and alpha-[Ru(azpy)2(guo)Cl]Cl, 5. The orientations of 9egua and guo in these complexes have been determined in detail with the use of 2D NOESY NMR spectroscopy. In 2 and 5, H8 is directly pointed toward the coordinated Cl, whereas, in 3 and 4, H8 is wedged between the pyridine and phenyl rings. The guanine derivatives in the azpy complexes can have more orientations than found for related cis-[Ru(bpy)2Cl2] species. This fluxionality is considered to be important in the binding of the alpha-bis(2-(phenylazo)pyridine)ruthenium(II) complex to DNA. In complex 1, ruthenium is the chiral center and in the binding to guanosine, two diastereoisomers each of adducts 4 and 5 have been clearly identified by NMR spectroscopy.     

Coordination of 9-ethylguanine to the mixed-ligand compound alpha-[Ru(azpy)(bpy)Cl2] (azpy = 2-phenylazopyridine and bpy = 2,2'-bipyridine). An unprecedented ligand positional shift, correlated to the cytotoxicity of this type of [RuL2Cl2] (with L = azpy or bpy) complex

The striking difference in cytotoxic activity between the inactive cis-[Ru(bpy)(2)Cl(2)] and the recently reported highly cytotoxic alpha-[Ru(azpy)(2)Cl(2)] (alpha indicating the isomer in which the coordinating Cl atoms, pyridine nitrogens, and azo nitrogens are in mutual cis, trans, cis orientation) encouraged the synthesis of the mixed-ligand compound cis-[Ru(azpy)(bpy)Cl(2)]. The synthesis and characterization of the only occurring isomer, i.e., alpha-[Ru(azpy)(bpy)Cl(2)], 1 (alpha denoting the isomer in which the Cl ligands are cis related to each other and the pyridine ring of azpy is trans to the pyridine ring of bpy), are described. The solid-state structure of 1 has been determined by X-ray structure analysis. The IC(50) values obtained for several human tumor cell lines have indicated that compound 1 shows mostly a low to moderate cytotoxicity. The binding of the DNA model base 9-ethylguanine (9-EtGua) to the hydrolyzed species of 1 has been studied and compared to DNA model base binding studies of cis-[Ru(bpy)(2)Cl(2)] and alpha-[Ru(azpy)(2)Cl(2)]. The completely hydrolyzed species of 1, i.e., alpha-[Ru(azpy)(bpy)(H(2)O)(2)](2+), has been reacted with 9-EtGua in water at room temperature for 24 h. This resulted in the monofunctional binding of only one 9-EtGua, coordinated via the N7 atom. The product has been isolated as alpha-[Ru(azpy)(bpy)(9-EtGua)(H(2)O)](PF(6))(2), 2, and characterized by 2D NOESY NMR spectroscopy. The NOE data show that the 9-EtGua coordinates (under these conditions) at the position trans to the azo nitrogen atom. Surprisingly, time-dependent (1)H NMR data of the 9-EtGua adduct 2 in acetone-d(6) show an unprecedented positional shift of the 9-EtGua from the position trans to the azo nitrogen to the position trans to the bpy nitrogen atom, resulting in the adduct alpha'-[Ru(azpy)(bpy)(9-EtGua)(H(2)O)](PF(6))(2) (alpha' indicating 9-EtGua is trans to the bpy nitrogen). This positional isomerization of 9-EtGua is correlated to the cytotoxicity of 1 in comparison to both the cytotoxicity and 9-EtGua coordination of cis-[Ru(bpy)(2)Cl(2)], alpha-[Ru(azpy)(2)Cl(2)], and beta-[Ru(azpy)(2)Cl(2)]. This positional isomerization process is unprecedented in model base metal chemistry and could be of considerable biological significance.     

Mononuclear and dinuclear complexes with a [Ru(tBu2PCH2CH2PtBu2)(CO)] core

Thermolysis of solid [Ru(d(t)bpe)(CO)2Cl2](2, d(t)bpe =(t)Bu2PCH2CH2P(t)Bu2) under vacuum affords the five-coordinate complex [Ru(d(t)bpe)(CO)Cl2] (4), which was shown by X-ray crystallography to contain a weak remote agostic interaction. In solution, 4 can be readily trapped by CO, CH3CN or water to give [Ru(d(t)bpe)(CO)(L)Cl2](L = CO, 2; L = CH3CN, 6; L = H2O, 7). Reaction of 4 with AgOTf/H2O yields the tris-aqua complex [Ru(d(t)bpe)(CO)(H2O)3](OTf)2 (8), which has been structurally characterised and probed in solution by pulsed-gradient spin echo (PGSE) NMR spectroscopy. The water ligands in 8 are labile and easily substituted to give [Ru(d(t)bpe)(CO)(NCCH3)3](OTf)2 (10) and [Ru(d(t)bpe)(CO)(DMSO)3](OTf)2 (11). In the presence of CO, the tris-aqua complex undergoes water-gas shift chemistry with formation of the cationic hydride species [Ru(d(t)bpe)(CO)3H](OTf) (12) and CO2. X-Ray crystal structures of complexes 2, 4, 6, 8 and 11-12 are reported along with those for [{Ru(d(t)bpe)(CO)}2(mu-Cl)2(mu-OTf)](OTf) (3), [{Ru(d(t)bpe)(CO)}2(mu-Cl)3][Ru(d(t)bpe)(CO)Cl3](5) and [Ru(d(t)bpe)(CO)(H2O)2(OTf)](OTf)(9).     

不同晶体结构MnO2纳米催化剂低温NH3-SCR性能研究

为了探究催化剂的结构和催化活性的关系,采用水热法制备了四种不同晶体结构的MnO₂纳米催化剂（α-MnO₂、β-MnO₂、γ-MnO₂和δ-MnO₂）,并考察了其低温NH₃-SCR活性。结果表明,不同晶体结构催化剂的活性不同,依次为γ-MnO₂ > α-MnO₂ > β-MnO₂ > δ-MnO₂,γ-MnO₂表现出最高的催化活性,NO_x转化率在150-260℃超过90%。随后,通过X射线衍射（XRD）、扫描电子显微镜（SEM）、N₂吸附-脱附、热重（TG）、红外光谱（FT-IR）、程序升温还原（H₂-TPR）及吡啶吸附红外光谱（Py-FTIR）等表征手段对催化剂的结构和性质进行分析。结果表明,α-MnO₂和β-MnO₂为纳米棒,γ-MnO₂和δ-MnO₂为纳米针,催化剂的比表面积并不是影响低温NH₃-SCR活性的主导因素。γ-MnO₂具有适宜的孔道结构、较强的氧化还原能力、丰富的化学氧含量和Lewis酸酸性位点,是其具有最高低温NH₃-SCR活性的原因。     

Linear-type S-bridged triruthenium complexes with aliphatic aminothiolate ligands: synthesis, characterization, and properties

Treatment of [RuCl(2)(DMSO)(4)] with 2-aminoethanethiol (Haet) in ethanol gave a dicationic triruthenium complex, [Ru[Ru(aet)(3)](2)]Cl(2) ([1]Cl(2)). Complex [1]Cl(2) was also obtained by treatment of RuCl(3).nH(2)O with excess Haet in water. When [1](2+) was chromatographed on a cation-exchange column of SP-Sephadex C-25, meso (DeltaLambda) and racemic (DeltaDelta/LambdaLambda) isomers of the corresponding tricationic complex, [Ru[Ru(aet)(3)](2)](3+) ([2](3+)), were eluted with aqueous NaNO(3). The racemic isomer of [2](3+) was optically resolved into DeltaDelta and LambdaLambda isomers by using [Sb(2)(R,R-tartrato)(2)](2-) as a resolving agent. The molecular structures of DeltaLambda- and DeltaDelta/LambdaLambda-[2](NO(3))(3) were determined by X-ray crystallography. In these complexes, the central Ru atom is coordinated by six thiolato groups from two terminal fac-(S)-[Ru(aet)(3)] units in an octahedral geometry, forming a linear-type S-bridged triruthenium structure. The spectroelectrochemical studies on the electronic absorption and CD spectra, together with the electrochemical studies, demonstrated that [1](2+) and [2](3+) are interconvertible with each other through a one-electron redox process, retaining the chirality of the triruthenium structure. Their electronic structures were investigated on the basis of EPR and magnetic susceptibility measurements, which indicated that [1](2+) and [2](3+) have spin ground states of S(t) = 0 and S(t) = 1/2, respectively. The corresponding L-cysteinato complex, [Ru[Ru(L-cys-N,S)(3)](2)](3-), which was formed from RuCl(3).nH(2)O and excess L-cysteine (L-H(2)cys) in water followed by air oxidation, is also presented.     

Oxidation of [Ru(NH3)5isn](BF4)2 by hyochlorous acid and chlorine in aqueous acidic media

UV-vis stopped-flow studies of the reaction of [Ru(NH3)5isn](2+) (isn = isonicotinamide) with excess HOCl at 25 degrees C demonstrate that it proceeds in two time-resolved steps. In the first step [Ru(NH3)5isn](3+) is produced with the rate law -d[Ru(II)]/dt = 2(aK(h)[H(+)] + b[H(+)][Cl(-)] + c[Cl(-)])[HOCl](tot)[Ru(II)]/(K(h) + [H(+)][Cl(-)]). Here, K(h) is 1.3 x 10(-3) M(2) and corresponds to the equilibrium hydrolysis of Cl2, a is (8.34 +/- 0.19) x 10(3) M(-2) s(-1) and represents the acid-assisted reduction of HOCl, b is (4.04 +/- 0.13) x 10(4) M(-1) s(-1) and represents the reduction of Cl2, and c is (6.25 +/- 0.59) x 10(2) s(-1) and represents the Cl(-)-assisted reduction of HOCl. In the second step [Ru(NH3)5isn](3+) undergoes further oxidation to a mixture of products with the rate law -d[Ru(III)]/dt = e[Ru(III)][HOCl]/[H(+)] where e is (1.18 +/- 0.01) x 10(-2) s(-1). This step is assigned a mechanism with Cl(+) transfer from HOCl to [Ru(III)(NH3)4(NH2)isn](2+) occurring in the rate-limiting step. These results underline the resistance of HOCl to act as a simple outer-sphere one-electron oxidant.     

Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity

Ru(II) eta6-arene complexes containing p-cymene (p-cym), tetrahydronaphthalene (thn), benzene (bz), or biphenyl (bip), as the arene, phenylazopyridine derivatives (C5H4NN:NC6H5R; R = H (azpy), OH (azpy-OH), NMe2 (azpy-NMe2)) or a phenylazopyrazole derivative (NHC3H2NN:NC6H5NMe2 (azpyz-NMe2)) as N,N-chelating ligands and chloride as a ligand have been synthesized (1-16). The complexes are all intensely colored due to metal-to-ligand charge-transfer Ru 4d6-pi* and intraligand pi -->pi* transitions (eta = 5000-63 700 M-1 cm-1) occurring in the visible region. In the crystal structures of [(eta6-p-cym)Ru(azpy)Cl]PF6 (1), [(eta6-p-cym)Ru(azpy-NMe2)Cl]PF6 (5), and [(eta6-bip)Ru(azpy)Cl]PF6 (4), the relatively long Ru-N(azo) and Ru-(arene-centroid) distances suggest that phenylazopyridine and arene ligands can act as competitive pi-acceptors toward Ru(II) 4d6 electrons. The pKa* values of the pyridine nitrogens of the ligands are low (azpy 2.47, azpy-OH 3.06 and azpy-NMe2 4.60), suggesting that they are weak sigma-donors. This, together with their pi-acceptor behavior, serves to increase the positive charge on ruthenium, and together with the pi-acidic eta6-arene, partially accounts for the slow decomposition of the complexes via hydrolysis and/or arene loss (t(1/2) = 9-21 h for azopyridine complexes, 310 K). The pKa* of the coordinated water in [(eta6-p-cym)Ru(azpyz-NMe2)OH2]2+ (13A) is 4.60, consistent with the increased acidity of the ruthenium center upon coordination to the azo ligand. None of the azpy complexes were cytotoxic toward A2780 human ovarian or A549 human lung cancer cells, but several of the azpy-NMe2, azpy-OH, and azpyz-NMe2 complexes were active (IC50 values 18-88 microM).     

Synthesis and intramolecular and interionic structural characterization of half-sandwich (arene)ruthenium(II) derivatives of bis(pyrazolyl)alkanes

Arene ruthenium(II) complexes containing bis(pyrazolyl)methane ligands have been prepared by reacting the ligands L' (L' in general; specifically L(1) = H(2)C(pz)(2), L(2) = H(2)C(pz(Me2))(2), L(3) = H(2)C(pz(4Me))(2), L(4) = Me(2)C(pz)(2) and L(5) = Et(2)C(pz)(2) where pz = pyrazole) with [(arene)RuCl(mu-Cl)](2) dimers (arene = p-cymene or benzene). When the reaction was carried out in methanol solution, complexes of the type [(arene)Ru(L')Cl]Cl were obtained. When L(1), L(2), L(3), and L(5) ligands reacted with excess [(arene)RuCl(mu-Cl)](2), [(arene)Ru(L')Cl][(arene)RuCl(3)] species have been obtained, whereas by using the L(4) ligand under the same reaction conditions the unexpected [(p-cymene)Ru(pzH)(2)Cl]Cl complex was recovered. The reaction of 1 equiv of [(p-cymene)Ru(L')Cl]Cl and of [(p-cymene)Ru(pzH)(2)Cl]Cl with 1 equiv of AgX (X = O(3)SCF(3) or BF(4)) in methanol afforded the complexes [(p-cymene)Ru(L')Cl](O(3)SCF(3)) (L' = L(1) or L(2)) and [(p-cymene)Ru(pzH)(2)Cl]BF(4), respectively. [(p-cymene)Ru(L(1))(H(2)O)][PF(6)](2) formed when [(p-cymene)Ru(L(1))Cl]Cl reacts with an excess of AgPF(6). The solid-state structures of the three complexes, [(p-cymene)Ru{H(2)C(pz)(2)}Cl]Cl, [(p-cymene)Ru{H(2)Cpz(4Me))(2)}Cl]Cl, and [(p-cymene)Ru{H(2)C(pz)(2)}Cl](O(3)SCF(3)), were determined by X-ray crystallographic studies. The interionic structure of [(p-cymene)Ru(L(1))Cl](O(3)SCF(3)) and [(p-cymene)Ru(L')Cl][(p-cymene)RuCl(3)] (L' = L(1) or L(2)) was investigated through an integrated experimental approach based on NOE and pulsed field gradient spin-echo (PGSE) NMR experiments in CD(2)Cl(2) as a function of the concentration. PGSE NMR measurements indicate the predominance of ion pairs in solution. NOE measurements suggest that (O(3)SCF(3))(-) approaches the cation orienting itself toward the CH(2) moiety of the L(1) (H(2)C(pz)(2)) ligand as found in the solid state. Selected Ru species have been preliminarily investigated as catalysts toward styrene oxidation by dihydrogen peroxide, [(p-cymene)Ru(L(1))(H(2)O)][PF(6)](2) being the most active species.